Literature DB >> 21109034

A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIV.

Eszter Somogyi1, Jianqing Xu, Agnes Gudics, József Tóth, Attila L Kovács, Franco Lori, Julianna Lisziewicz.   

Abstract

We describe here a single plasmid DNA immunogen representing the broadest antigen repertoire among HIV vaccine candidates. This pDNA was "ANTIGENeered" for the regulated expression of thirteen complete and two non-functional HIV protein antigens. These proteins self assemble into complex virus-like particles (VLP(+)). Multiple irreversible safety features were introduced by genetic modifications including the complete impairment of integration, reverse transcription, the function of Nef and the 3'LTR. Epitope analysis predicted that the pDNA-derived protein repertoire can potentially present over 3000 T cell epitopes. However, the expressed antigens have different potential to induce HIV-specific CD4(+) and CD8(+) T cells supporting our hypothesis that HIV vaccines should contain all possible regulatory and structural proteins. This immunogen is the active pharmaceutical ingredient of DermaVir, a therapeutic vaccine product candidate that recently successfully completed Phase II clinical trials and meets the safety, immunogenicity and cost requirements of an HIV vaccine. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21109034     DOI: 10.1016/j.vaccine.2010.11.019

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  DNA nanoparticles with core-shell morphology.

Authors:  Preethi L Chandran; Emilios K Dimitriadis; Julianna Lisziewicz; Vlad Speransky; Ferenc Horkay
Journal:  Soft Matter       Date:  2014-08-19       Impact factor: 3.679

2.  Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial.

Authors:  Benigno Rodriguez; David M Asmuth; Roy M Matining; John Spritzler; Jeffrey M Jacobson; Robbie B Mailliard; Xiao-Dong Li; Ana I Martinez; Allan R Tenorio; Franco Lori; Julianna Lisziewicz; Suria Yesmin; Charles R Rinaldo; Richard B Pollard
Journal:  J Acquir Immune Defic Syndr       Date:  2013-12-01       Impact factor: 3.731

3.  Exploitation of Langerhans cells for in vivo DNA vaccine delivery into the lymph nodes.

Authors:  E R Tőke; O Lőrincz; Z Csiszovszki; E Somogyi; G Felföldi; L Molnár; R Szipőcs; A Kolonics; B Malissen; F Lori; J Trocio; N Bakare; F Horkay; N Romani; C H Tripp; P Stoitzner; J Lisziewicz
Journal:  Gene Ther       Date:  2014-04-03       Impact factor: 5.250

4.  Structure and biological activity of pathogen-like synthetic nanomedicines.

Authors:  Orsolya Lőrincz; Enikő R Tőke; Eszter Somogyi; Ferenc Horkay; Preethi L Chandran; Jack F Douglas; János Szebeni; Julianna Lisziewicz
Journal:  Nanomedicine       Date:  2011-08-10       Impact factor: 5.307

5.  Single DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals.

Authors:  Julianna Lisziewicz; Nyasha Bakare; Sandra A Calarota; Dénes Bánhegyi; János Szlávik; Eszter Ujhelyi; Enikő R Tőke; Levente Molnár; Zsolt Lisziewicz; Brigitte Autran; Franco Lori
Journal:  PLoS One       Date:  2012-05-09       Impact factor: 3.240

Review 6.  Developments in HIV-1 immunotherapy and therapeutic vaccination.

Authors:  Peter Lawrence Smith; Helen Tanner; Angus Dalgleish
Journal:  F1000Prime Rep       Date:  2014-06-02

Review 7.  A Defective Viral Particle Approach to COVID-19.

Authors:  Maria Kalamvoki; Vic Norris
Journal:  Cells       Date:  2022-01-17       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.